Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ultragenyx Pharmaceutical (RARE) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Q3 2025 value amounting to -$1.81.

  • Ultragenyx Pharmaceutical's EPS (Basic) fell 2928.57% to -$1.81 in Q3 2025 from the same period last year, while for Sep 2025 it was -$5.93, marking a year-over-year increase of 719.87%. This contributed to the annual value of -$6.3 for FY2024, which is 2361.43% up from last year.
  • According to the latest figures from Q3 2025, Ultragenyx Pharmaceutical's EPS (Basic) is -$1.81, which was down 2928.57% from -$1.17 recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's EPS (Basic) registered a high of -$1.08 during Q3 2021, and its lowest value of -$3.5 during Q3 2022.
  • In the last 5 years, Ultragenyx Pharmaceutical's EPS (Basic) had a median value of -$1.81 in 2021 and averaged -$1.9.
  • As far as peak fluctuations go, Ultragenyx Pharmaceutical's EPS (Basic) plummeted by 53095.24% in 2021, and later surged by 3721.97% in 2024.
  • Over the past 5 years, Ultragenyx Pharmaceutical's EPS (Basic) (Quarter) stood at -$1.79 in 2021, then decreased by 20.67% to -$2.16 in 2022, then skyrocketed by 33.33% to -$1.44 in 2023, then decreased by 3.36% to -$1.49 in 2024, then fell by 21.61% to -$1.81 in 2025.
  • Its EPS (Basic) was -$1.81 in Q3 2025, compared to -$1.17 in Q2 2025 and -$1.57 in Q1 2025.